Loading...
•
Jun 30, 2022
Beauty Health Q2 2022 Earnings Report
Reported record financial results, exceeding expectations and raised net sales guidance for 2022.
Key Takeaways
BeautyHealth announced record second-quarter results with net sales growth of 55.7% year-over-year, reaching $103.5 million. The company raised its full-year net sales guidance and reaffirmed its adjusted EBITDA outlook, driven by strong demand for HydraFacial delivery systems and healthy consumer interest.
Net sales increased by 55.7% year-over-year to $103.5 million.
Net income reached $7.9 million, a significant improvement compared to a net loss of $139.4 million in the same quarter last year.
Adjusted EBITDA grew by 10.9% to $12.6 million.
Americas net sales increased by 76.6% year-over-year, driven by strong demand for Syndeo.
Beauty Health
Beauty Health
Beauty Health Revenue by Segment
Beauty Health Revenue by Geographic Location
Revenue by Segment
Delivery Systems Revenue
CapyFin.comConsumables Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comAPAC Revenue
CapyFin.comEMEA Revenue
CapyFin.com Forward Guidance
BeautyHealth increased its fiscal 2022 net sales guidance to a range of $340.0 million to $350.0 million and reaffirmed its 2022 adjusted EBITDA outlook of approximately $50.0 million.
Positive Outlook
- Increased fiscal 2022 net sales guidance reflects management's confidence in the business.
- Reaffirmation of 2022 adjusted EBITDA outlook indicates continued profitability expectations.
- Guidance assumes no material deterioration in general market conditions.
- Company continues to expect up to $20.0 million of capital expenditures to be incurred during 2022.
- The increase reflects management's confidence in the business as the Company executes against its growth plan.
Challenges Ahead
- Achievement of anticipated results is subject to risks and uncertainties disclosed in SEC filings.
- Outlook does not account for unanticipated developments, changes in operating environment, acquisitions, dispositions, or financings during 2022.
- Company remains cautious of potential risks from COVID-19 strains and uneven global vaccine adoption.
- Inflationary headwinds related to higher raw material, shipping, and labor costs are a concern.
- Outlook assumes a largely reopened global market, which could be negatively impacted by closures or restrictive measures.
Revenue & Expenses
Visualization of income flow from segment revenue to net income